Societe Generale set a €94.00 ($116.05) price objective on Sanofi (EPA:SAN) in a research note released on Thursday. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently weighed in on the stock. Berenberg Bank set a €97.00 ($119.75) price target on shares of Sanofi and gave the stock a neutral rating in a research note on Thursday, November 2nd. set a €78.00 ($96.30) price target on shares of Sanofi and gave the stock a neutral rating in a research note on Friday, November 3rd. UBS Group set a €82.00 ($101.23) price target on shares of Sanofi and gave the stock a neutral rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a price target on shares of Sanofi in a research note on Thursday, November 2nd. Finally, Morgan Stanley set a €92.00 ($113.58) target price on shares of Sanofi and gave the stock a buy rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company. Sanofi currently has an average rating of Hold and an average target price of €84.63 ($104.48).

Sanofi (EPA:SAN) opened at €63.39 ($78.26) on Thursday. Sanofi has a one year low of €63.09 ($77.89) and a one year high of €92.97 ($114.78). The firm has a market cap of $80,070.00 and a price-to-earnings ratio of 20.99.

ILLEGAL ACTIVITY NOTICE: “Sanofi (SAN) Given a €94.00 Price Target at Societe Generale” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://theolympiareport.com/2018/02/11/sanofi-san-given-a-94-00-price-target-at-societe-generale.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.